Hilja Ibert joined miDIAGNOSTICS as Chief Executive Officer in February 2016. Together with the miDIAGNOSTICS research partners imec and Johns Hopkins University, she and her team will develop the first miDIAGNOSTICS product portfolio and will engage with global diagnostics and pharmaceutical companies for the go-to-market endeavors. Until January 2016, Ms. Ibert was Vice President and General Manager of Hologic Diagnostics Solutions International, a global player in the field of breast health, surgical and clinical diagnostics, for which she initially worked as Vice President and General Manager of Hologic Europe. Previously, Dr. Ibert worked for Becton Dickinson and bioMerieux, both leading players in the medical device and diagnostics market. Over the course of more than 20 years with both companies, she developed her expertise in numerous international leadership and management roles. Dr. Ibert holds a Ph.D in Microbiology and a Degree in Nutritional Sciences from the Rheinische Friedrich Wilhelms Universität of Bonn, Germany.
Bob Bollinger has led the R&D team at Johns Hopkins University since October 2015 and was instrumental in developing the plan for developing miDIAGNOSTICS’ technology. Additionally, he serves as the Founding Director of the Center for Clinical Global Health Education at Johns Hopkins University. Dr. Bollinger received his MD from Dartmouth College and MPH from Johns Hopkins University.
Peter Peumans has led life science activities at imec since 2011. Dr. Peumans' team develops silicon chips customized for diagnostics and life science research in close partnership with customers. From 2004 to 2010, he was an assistant professor of Electrical Engineering at Stanford University, where he pursued solar energy conversion and biomedical electronics. He received an NSF CAREER award in 2005. Dr. Peumans is a frequently invited speaker, has published over 70 peer-reviewed publications, and holds more than 30 patents. Dr. Peumans earned his undergraduate and master degrees in Electrical Engineering summa cum laude at the Katholieke Universiteit Leuven, Belgium and obtained his PhD in Electrical Engineering at Princeton University.
Luc Van den hove has served as President and Chief Executive Officer (CEO) of imec since July 1, 2009. Before holding this position he was Executive Vice President and Chief Operating Officer after first joining imec, where his research career started in the field of silicide and interconnect technologies, in 1984. In 1988, he became manager of imec’s micro-patterning group (lithography, dry etching); in 1996, Department Director of Unit Process Step R&D; and in 1998, Vice-President of the Silicon Process and Device Technology Division. In January 2007, he was appointed as imec's Executive Vice President & Chief Operating Officer (COO). Under his guidance, imec has grown to an organisation with a staff of around 2400 people, operating with an annual budget of around 415M€ (2015) and with offices in Belgium, the Netherlands, US, Japan, Taiwan, China and India. Currently, Dr. Van den hove is also professor of Electrical Engineering at the University of Leuven. He is also a member of the Technology Strategy Committee of ASML. He has authored or co-authored more than 150 publications and conference contributions. He is a frequently solicited speaker on technology trends and applications for nano-electronics at major top conferences. He has presented more than 30 keynote presentations. Dr. Van den hove received his Ph.D. in Electrical Engineering from the University of Leuven, Belgium.
Marc Coucke is a serial entrepreneur who is, through Alychlo NV, investing in funds and fast-growing (Belgian) enterprises. He spreads his business across several sectors: healthcare, pharmaceutical industry, project development, high-tech IT innovations, art, sports,… . Health, jobcreation, growth and innovation are the main targets of his investments. In 1987 Mr. Coucke was also the founding father of Omega Pharma, that grew -under his leadership- both organically and externally into a leading European OTC pharmaceuticals company. In 2015, Omega Pharma was acquired by Perrigo. Mr. Coucke graduated as a Qualified Pharmacist from the State University of Ghent, Belgium, and holds an MBA from the Vlerick Business School, Ghent, Belgium
Michel Akkermans is a serial entrepreneur, private investor, advisor and board member, serving on the boards of public and private companies and private equity funds. For a complete list, please refer to www.pamica.be. He was co-founder, Chairman and CEO of Clear2Pay, a finance technology company focused on global payment solutions, before it was acquired by FIS (Nasdaq: FIS) in 2014. Before Clear2Pay, Mr. Akkermans was founder, CEO and Chairman of FICS, a fintech company specialized in online banking and compliance reporting. In 1999, FICS merged with Security First Technologies, creating the leader in Internet banking - S1 Corporation (Nasdaq: SONE), with Mr. Akkermans as its chairman. He also was executive chairman of Data4S, a data analytics specialist, focusing on anti-money laundering applications. Norkom acquired the company in 2004. Clear2Pay, FICS and Data4S generated superior returns for their investors and management teams. Mr. Akkermans holds a M.S. in electronic engineering and computer sciences and a degree in economics and finance from the University of Leuven, Belgium.
Roald Borré serves as Head of Equity Investments at Participatiemaatschappij Vlaanderen NV (PMV), which he joined in 2011 after a period of five years as an entrepreneur. Mr. Borré serves as Manager of PMV-TINA. He started his professional career at the Financieel Economische Tijd as a Financial Analyst, specialized in high tech companies in the field of ICT and Biotech. In 1999, he joined Puilaecto Private Bankers as Senior Fund Manager and managed various investment funds in various fields of innovation, a position he held until 2006. He serves as a Non-Executive Director of Biocartis Group NV and as a Board Member in several portfolio companies. He is a Member of a number of advisory boards. Mr. Borré received his Masters Degree in Economic and Financial Sciences from Hogeschool-Universiteit Brussels, Belgium.
Dr. Ralph Hruban is a Professor of Pathology and Oncology and Director of the Department of Pathology at the Johns Hopkins University School of Medicine. He received his undergraduate degree from the University of Chicago and is a 1985 Johns Hopkins School of Medicine alumnus.
He completed his residency training at Hopkins and he spent one year as a Fellow at Memorial Sloan-Kettering Cancer Center in New York. After completing his fellowship, Dr. Hruban returned to Johns Hopkins in 1990 to join the faculty
Dr. Hruban is currently also the Director of The Sol Goldman Pancreatic Cancer Research Center at Johns Hopkins. The pancreatic cancer research team at Johns Hopkins contains many of the world’s leading experts in pancreatic cancer. Through their extensive research, they have discovered many of the fundamental genetic changes that drive pancreatic cancer.
Dr. Hruban has received numerous awards including the Arthur Purdy Stout Prize for significant career achievements in surgical pathology, the Ramzi Cotran Award from the United States and Canadian Academy of Pathology, the PanCAN Medical Visionary Award, the Team Science Award from the American Association for Cancer Research, the Ruth Brufsky Award for Excellence in Clinical Research for Pancreatic Cancer, the Frank H. Netter Award for Special Contributions to Medical Education, the Ranice W. Crosby Distinguished Achievement Award for scholarly contributions to the advancement of art as applied to the sciences, the Ruth Leff Siegel Award for Excellence in Pancreatic Cancer Research, and the 2013 Johns Hopkins University Distinguished Alumni Award. In 2013 he was elected a member of the German National Academy of Sciences Leopoldina. He is recognized by ExpertScape.com as the leading expert in the world on pancreatic cancer. Dr. Hruban has also received five teaching awards from the Johns Hopkins University School of Medicine, including the Educational Innovation Award
Dr. Hruban has written more than 700 scientific papers, 80 book chapters and reviews, and five books. His research contributions include the characterization of “PanINs,” the precursor lesions that give rise to invasive pancreatic cancer. He received recognition from the Institute for Scientific Information as a highly cited researcher and from Essential Science Indicators as the most highly cited pancreatic cancer scientist. In addition to his research efforts, Dr. Hruban founded The National Familial Pancreas Tumor Registry at Johns Hopkins and helped to create the Johns Hopkins Pancreatic Cancer Web Page. He created an award-winning iPad application to teach pancreas pathology, as well as iPhone and iPAD apps for patients with pancreatic cancer, and recently produced an award-winning documentary on the life of William Stewart Halsted.
Pieter Bourgeois is an Investment Manager at Alychlo NV, the investment firm of Belgian entrepreneur Marc Coucke. Prior to this, Mr. Bourgeois worked in different financial roles focusing on M&A and strategic projects, gaining business acumen in a variety of sectors and different sizes of companies. Mr. Bourgeois holds a Masters Degree in Industrial Engineering and is an MBA from the Solvay Brussels School of Economics & Management.
David Dessers is Managing Partner of Cresco, a business law firm. He is an experienced business lawyer with a strong focus on the technology sector. Mr. Dessers frequently assists entrepreneurs and companies in their business and fundraising activities, working with entrepreneurs and senior management during all stages of the private company lifecycle including start-up, seed funding, venture capital and debt financing, acquisitions and dispositions, as well as employment, equity incentive, contracting and intellectual property needs. He advises clients regularly with respect to complex commercial transactions designed to protect and maximize the value of technology assets, including technology licenses and acquisitions, research and development collaborations, and corporate partnering transactions.
Andreas Weimann is Managing Director of Labor Berlin (Germany), Europe's largest hospital laboratory. He is a specialist in laboratory hematology with a key interest in SIRS/Sepsis diagnostics, CSF analytics and molecular risk diagnostics. Mr. Weimann serves as Vice President of the National Professional Union of Accreditaed Laboratories in Germany (ALM e.V. Mr. Weimann holds M.D., M.A. and M.H.B.A. degrees)
Jean-Claude Deschamps started as a systems engineer at IBM, Endicott (NY) in 1961, and returned to Europe in 1963 to work in the electrical engineering-industry. After serving as Managing Director of Gardy S.A. (Benelux), he moved to Group-VPt (Geneva, Switzerland) in 1971 to oversee their French and Benelux operations. Following the merger with Merlin-Gerin SA (Grenoble, France) in 1976 he focused on this integration. From its inception in 1970 until 1981 he was Chairman & Managing Director of Telindus N.V., a Gardy-Merlin Gerin Group company focusing on data-communications engineering, meant as a diversification outside the electric engineering-industry. Since 1981, he has worked as an independent project-consultant & financial engineer with involvement in over 50 projects and companies, principally with a technological and industrial challenge. Jean-Claude Deschamps has had close relations with Gimv since the early 1980s and has held numerous assignments for Gimv. Within the Gimv-group he is presently in charge of its Asian network and it is in this capacity that he is chairing Gimv’s Asian Advisory Council. In addition to a conservative number of board positions, he has served from 2000 to 2009 as special advisor to Belgium’s Flemish government, among other things regarding its shareholding in Gimv, and several other industrial participations of their portfolio. Jean-Claude Deschamps holds a Master Degree in mechanical and electrical engineering from the University of Ghent, Belgium, a postgraduate degree from the Eidgenössische Technische Hochschule in Zürich, Switzerland and an MBA from the Vlerick Business School, Ghent, Belgium.
Dr. Ajit Shetty started his career in the Life Sciences sector at Janssen Pharmaceutica and moved through functions in finance, business development and supply chain to chairman of Janssen Pharmaceutica Beerse for the period 1999-2008. He served on the J&J Corporate Operating Committee reporting to the Chairman of J&J with responsibility for the firm’s entire supply chain of Medical Devices, Pharmaceutical and Consumer divisions. He currently serves as Member of the Board of the Flemish Institute of Biotechnology, the Institute of Tropical Medicine Antwerp, as a Trustee of Carnegie Mellon University as well as other Board positions. He formerly served on the Advisory Committee of the Carey Business School at Johns Hopkins University. Dr. Shetty holds a Masters and PhD in Metallurgy from Cambridge University, UK, and an MBA from Carnegie Mellon University.